First bronchiectasis patient dosed in Phase III trial to study brensocatib
The first patient with bronchiectasis has been dosed in the Phase III ASPEN study of brensocatib, a reversible inhibitor of dipeptidyl peptidase 1.
List view / Grid view
The first patient with bronchiectasis has been dosed in the Phase III ASPEN study of brensocatib, a reversible inhibitor of dipeptidyl peptidase 1.
The EMA CHMP has revealed its suggestion to grant marketing authorisation to seven medicines after its most recent meeting.